In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, discusses how she's using her in-practice experience as an OB-GYN to inform Organon's strategic approach to addressing maternal health challenges.
Fundamentally, one of the things I love the most about being obstetrician gynecologist is really advocating and educating, inspiring, empowering women. Specifically bringing the voice of the patient from real life experiences into the center of what we do, being present in the community and listening to what they need to, listening to how they're perceiving and understanding what are their challenges every day, before, during and after the healthcare experience, and then also gathering the same information from providers and communities and really recognizing that a key element of sustainable change is addressing these health disparities and the social drivers of health throughout my practice.
I've seen way too many patients who need this sort of help and doing what I can to support them throughout their birth journey, which should be a joyful experience for Mom and baby, but I've also seen firsthand how the impact of birth complications on that mom and her family, and really bringing that empathetic perspective into what we do, and encouraging my teens, when we're thinking about our work, to put ourselves in the shoes of that Woman, of that mom, to really consider her holistically, which really includes not only in that moment, but before, during after, and figuring out how those social drivers really affect our health.
As you know, Organon is one of the very few healthcare companies solely focused on advancing women's health, and we've seen the positive impact that cross collaboration at all layers, private and public and sector in the community area, how that collaborative approach makes a difference every day in the lives of a woman in her community, because it starts with her perspective, and from there, we understand what are the unmet needs, and how can We address those across maternity, maternity, maternal health conditions, but also conditions that affect her at all stages of her life journey.
Our research approach is really guided by a team of experts, including OBGYN PhDs, nurses and pharmacists who really understand this and who are passionate about this. Every day, we are constantly listening to women and to their healthcare providers to really understand that we're infusing the science with the realities of their day to day life, when and if to start a family is a really personal and important decision for women, and we want to make sure that all women have the opportunity to Access the best care that they can across the lifespan that they own, we are committed to partnering with healthcare community entities to really close this gap for both maternal health and reproductive health and life health so that we can accelerate meaningful change in the lives of women their families and the communities that they love and serve.
IMF Chief Medical Officer Discusses Global Initiatives to Improve Myeloma Treatment
August 20th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
AbbVie Presents New Data from Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024
June 13th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses data presented at ASCO from ABBV-400 and ABBV-706 in multiple studies.
Planning for Unique Challenges Faced by Cell & Gene Therapy Developers
May 8th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, discusses the unique challenges that developers of cell and gene therapies need to plan for when building their channel strategy.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.